AD/PD meeting in Vienna

March 28, 2017

Meet NeuroProof at the Annual Meeting for Alzheimers and Parkinson's Disease AD/PD 2017 in Vienna and discuss our newest functional assay for screening Alzheimer drugs on a human genetic APP-mutant cell culture model with Benjamin Bader at the poster on Thursday. We also present a new approach for comparing functional phenotypic effects of alpha-synuclein on mouse and human dopaminergic neurons. Visit the AD/PD website for the abstract:


Stem cells in drug discovery

March, 6-7th 2016, Cambridge

Meet NeuroProof Project Manager Benjamin  Bader at the Conference on Advances in Drug Discovery and discuss the latest NeuroProof assays for functional phenotypic CNS drug discovery using human stem cells.

Further information:

2nd Annual Conference on Neuroscience R&D Technologies

September, 29-30th 2016, London

Meet NeuroProof CEO Olaf Schröder at the 2nd Annual Conference on Neuroscience R&D Technologies conference and discuss the presentation and latest NeuroProof assays for functional phenotypic CNS drug discovery.

Further information:

NeuroProof at Axiogenesis Meeting in Cologne

September 7-9th 2016

NeuroProof project manager Dr. Benjamin Bader presented the latest results on functional phenotypic modeling of neuro-degenerative diseases using human iPSC-derived neurons and their comparison to well-known primary cell cultures growing on micro-electrode arrays. The topics presented include effects of alpha-synuclein and botulinum toxin on hIPSC derived neuronal networks.

MEA meeting 2016

Reutlingen, June 28th - July 1st

ISSCR stem cell meeting

San Francisco, 22-26.6.2016

If you are attending the ISSCR meeting in San Francisco, come visit our two NeuroProof contributions: 1) The poster by Nagel et al. about functional evaluation of Axol's patient-derived iPSC neurons carrying a presinilin-1 mutation presented by Naomi Wessel-Carpenter and 2) the poster by Bader et al. about multi-parametrically characterizing the functional in vitro phenotype of Axiogensis' different "4U" neuron series with data on seizurogenic compounds and on our novel phenotypic readout used for phenotypic in vitro disease modeling (here Parkinson) which is presented by Elena Kfoury.

World Preclinical Congress

Boston, 14-17.6.2016

NeuroProof and Axiogenesis present a poster about " Monitoring and adapting the functional phenotypic of developing human iPSC-derived neuronal networks using multi-variate analysis of MEA data". Visit out poster and discuss the latest developments in multi-parametric data analysis for phenotypic screening of human iPSC-derived neurons.

Channelopathy Meeting 2016

Paris, 15-17.6.2016

Meet Alexandre Fouassier in Paris who presents some of our work on modulating neuronal receptors in human iPSC-derived neurons.

Ono Pharmaceuticals and NeuroProof at the 31st International Conference of Alzheimer's Disease International (ADI)

21-24 April 2016, Budapest

Ono Pharmaceuticals and NeuroProof co-presented novel functional in vitro results on the electrophysiological Characterization of GABA-A alpha5 negative allosteric modulators in hippocampal neurons and their efficacy to rescue amyloid beta-induced effects compared to standard of care and known pro-cognitive agents. See "Publications" for more information.

High Content & Phenotypic Screening 2016

Cambridge, UK. 10.05.2016

NeuroProof and Axiogenesis present newest results on how to "shift and rescue functional phenotypes for in vitro disease modeling – linking human iPSC-derived dopaminergic neurons with multi-parametric analysis of electrophysiological MEA data.” We show how the midbrain-like functional phenotype of human iPSC dopaminergic neurons is affected by Parkinson-related toxins and how this can be rescued in vitro. Looking forward to getting your comments and questions.

Meeting link: